SERB signs agreement to acquire Idefirix rights for $133.6m

​SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix from Hansa Biopharma for a total of $133.6m.

The post SERB signs agreement to acquire Idefirix rights for $133.6m appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Sunrise Group secures FDA clearance for home sleep test
BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint
Hospital at home: the new model of modern care
Boston Scientific invests $1.5bn for equity stake in MiRus
First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us